Silexion Therapeutics Corp
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
1.18M
on 2026-06-30, from 58K on 2025-03-31 10-Q ↗
Earlier counts are adjusted for the 1-for-15 and 1-for-10 reverse splits; each bar's tip shows the count as filed.
Counts before 2025-03-31 are left out: the count went from 12.3M on 2024-12-31 to 58K on 2025-03-31, a change no split on file explains.
a raise that quarter, at its price
$13.2M
H.C. Wainwright, agreement of 2025-09-26. No at-the-market sales statement read from a 10-Q or 10-K. 8-K ↗
Warrants
6
Warrants of every class as tagged in the XBRL facts on 2024-08-06. Adjusted for the 1-for-15 and 1-for-10 reverse splits. 10-K ↗
Cash
0.7 quarters
$2.2M on 2026-06-30 ÷ $3.1M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-08-11 | Public offering incl. 1.82M pre-funded | 3,846,161 | $0.65 | not read | 424B4 ↗ |
| 2025-09-11 | Public offering incl. 0.11M pre-funded, with warrants at $4.00 | 1,500,000 | $4.00 | $6.0M | 424B4 ↗ |
| 2025-01-15 | Public offering incl. 1.56M pre-funded, with warrants at $1.35 | 3,703,703 | $1.35 | $5.0M | 424B4 ↗ |
Also on file: a 1-for-15 reverse split, 2025-07-28 8-K ↗ · a 1-for-10 reverse split, 2026-01-01 8-K ↗ · a 1-for-10 reverse split, 2026-07-21 8-K ↗